clinical trial · NCT06510374
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder CancerNadofaragene Firadenovec
brief summary
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
started
Oct 1, 2024
primary completion
Jun 30, 2028
completion
Jun 30, 2031
last updated
Jul 1, 2026
official title
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol